Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

J. L. Van Laethem,Ph. van Maele,Chris Verslype,Marc Polus,Anne Demols,Gh. Houbiers,Philip Caenepeel,A. Leleux,R.R. Vermaut,E. Van Cutsem,Marc Peeters

Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

2004

J. L. Van Laethem
Ph. van Maele
Chris Verslype
Marc Polus
Anne Demols
Gh. Houbiers
Philip Caenepeel
A. Leleux
R.R. Vermaut
E. Van Cutsem
Marc Peeters

Objectives: This multicenter phase II study was designed to determine the activity and tolerance of gemcitabine and raltitrexed in advanced pancreatic adenocarcinoma. Patie

Keywords:

Phases of clinical research
Fluorouracil
Oncology
Pathology
Folinic acid
Pancreatic cancer
Deoxycytidine
Gemcitabine
Raltitrexed
Medicine
Surgery
Internal medicine
Adenocarcinoma
Regimen
Gastroenterology
Progressive disease
Neutropenia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations